On Demand ACAAI 2023 Annual Scientific Meeting General Sessions

Cost: $345 for College members, $425 for non-members.

You can earn up to 60.25 AMA PRA Category 1 Credits™. This collection covers sessions from Friday, Saturday, Sunday, and Monday.

Sessions included:

Are You Using These Diagnostic Tests to Maximal Efficacy?
The Environment and the Allergist - Pollen and Practice Changes in the New Environment
The Evolution of Immunodeficiency Due to Medications and Malignancy
EAACI - New Responses to the Theoretical and Practical Challenge of Allergic Diseases
Respiratory Conditions We Need More Help With
Empowering Adolescents and Young Adults for Lifelong Health
Complex Non-IgE Food Allergy and Extreme Food-related Anxiety
Presidential Plenary - Trending Topics in Allergy and Immunology
Editor's Pick - Best Articles from Annals of Allergy, Asthma and Immunology
Is There a Mild Food Allergy Phenotype?
Recent Advances in Diagnosis and Monitoring of Respiratory Conditions
Physical Urticaria Provocation: Diagnostics and Interpretation
Reimbursement for Technology Enabled Services
The Changing Landscape of Primary Immunodeficiency
7 for 11 - Hot Topics in Pediatrics A&I - A Joint Presentation from AAP-SOAI & ACAAI
Challenging Symptoms to Manage in Rhinosinusitis / Airway Diseases
Climbing the Baked Egg/Milk Ladder: Is It As Safe As We Assume?
From Bleach Baths to Biologics: Evidence and Recommendations From the 2023 Atopic Dermatitis Parameters
Chronic Spontaneous Urticaria: Itching for the Latest Information
Plenary: The Buzz on Biologics: To Asthma and Beyond
Being In The Know With ABAI
Coding & Government Relations
Community/Academic Allergist Initiative: Community Allergist Partnership* in Education (CAPE)
Asthma: The Good, the Bad, and the Ugly
Hot Topics and Practical Pearls in Dermatology
Primary Prevention Strategies for Asthma
ProCon - Skin Testing vs Serum Testing for the Diagnosis of Venom Allergy
Jeopardy - What's That Rash?
Introductory Course in Rhinolaryngoscopy
Allergen Immunotherapy in Your Practice - Are You Up to Date with the Current Parameters?
An Ounce of Prevention in Food Allergy
The Ever-Changing Landscape of COVID-19
Plenary - Don't Be Scared of the Skin: Practical Pearls to Treat Urticaria and Atopic Dermatitis
Evolutions in Anaphylaxis
Inborn Errors of Immunity - Insights From the Practice Parameter Update
WAO - World Allergy Forum - Allergen Immunotherapy Update
Drug Allergy in Evolving Patient Care
Supplements, Immune Boosting, Special Diets & Cannabis: What Every Allergist Needs to Know
AACA: Updates from the Allergen Immunotherapy Primer

Release Date: 12/1/2023
Expiration Date: 11/30/2026

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 60.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Additional information

Disclosure:

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines a “ineligible company” as companies whose primary business is producing, marketing, selling, re-selling, or distributing health care goods or services, used by or on patients. Examples of such organizations include:

•   Advertising, marketing, or communication firms whose clients are ineligible companies
•   Bio-medical startups that have begun a governmental regulatory approval process
•   Compounding pharmacies that manufacture proprietary compounds
•   Device manufacturers or distributors
•   Diagnostic labs that sell proprietary products
•   Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•   Manufacturers of health-related wearable products
•   Pharmaceutical companies or distributors
•   Pharmacy benefit managers
•   Reagent manufacturers or sellers

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.
Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.
Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified relevant financial relationships have been mitigated.